Brief: New Phase IIB/III Clinical Data Demonstrates Over Three Years Of Continuous Treatment With Oral Blarcamesine To Significantly Benefit Early Alzheimer’S Disease Patients
13/01/2025 13:48
Jan 13 (Reuters) - Anavex Life Sciences Corp AVXL.O :
* NEW PHASE IIB/III CLINICAL DATA DEMONSTRATES OVER THREE
YEARS OF
CONTINUOUS TREATMENT WITH ORAL BLARCAMESINE TO SIGNIFICANTLY
BENEFIT EARLY ALZHEIMER’S DISEASE PATIENTS
* ANAVEX LIFE SCIENCES CORP: TOPLINE ATTENTION-AD TRIAL:
PATIENTS
SHOWED IMPROVED COGNITION AND FUNCTION OVER THREE YEARS
* ANAVEX LIFE SCIENCES CORP: BLARCAMESINE EXHIBITED A
FAVORABLE
SAFETY PROFILE WITH NO TREATMENT-RELATED DEATHS
Source text: ID:nGNX3PtQ7R
Further company coverage: AVXL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board